hexobarbital has been researched along with 1-(3-chlorophenyl)piperazine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Aota, M; Harada, K; Inoue, T; Ishibashi, K; Matsuda, R; Matsuoka, N; Mihara, T; Yamaji, T | 1 |
2 other study(ies) available for hexobarbital and 1-(3-chlorophenyl)piperazine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
Topics: Animals; Anti-Anxiety Agents; Buspirone; Calcium; Calcium Signaling; Central Nervous System Depressants; CHO Cells; Cricetinae; Diazepam; Drug Interactions; Ethanol; Exploratory Behavior; Feeding Behavior; Hexobarbital; Hypnotics and Sedatives; Interpersonal Relations; Male; Mesylates; Motor Activity; Neurotransmitter Transport Proteins; Piperazines; Postural Balance; Quinazolines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin Antagonists; Sleep | 2006 |